3 Shares Carrying Market-Beating Yields In 2015: AstraZeneca plc, Standard Life Plc And Aviva plc

Royston Wild explains why AstraZeneca plc (LON: AZN), Standard Life Plc (LON: SL) and Aviva plc (LON: AV) should attract income chasers for next year.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Today I am looking at three blue-chip winners set to deliver stunning returns in 2015.

AstraZeneca

The crushing impact of patent expirations across key products is expected to keep earnings growth at AstraZeneca (LSE: AZN) (NYSE: AZN.US) underwater for some time to come. Even though the firm has ramped up R&D to compensate for the loss of these labels, the effect of exclusivity losses is expected to push earnings 18% and 4% lower in 2014 and 2015 respectively.

As a result, AstraZeneca is expected to keep the full-year payout locked at 280 US cents per share in both 2014 and 2015. Still, the yield still clocks in at a tasty 3.7% through to the end of next year, taking out a forward average of 3.2% for the complete FTSE 100.

AstraZeneca will have to keep the lab bench buzzing to create the next generation of earnings drivers and get dividends moving higher once again. Although the business of drugs development is fraught with pitfalls, I believe that the pharma giant’s refreshed development strategy — allied with its proactive acquisition strategy in key growth areas and success in developing markets — should generate excellent returns in coming years.

Standard Life

Even though Standard Life (LSE: SL) has seen earnings fluctuate wildly in recent years, brought on by industry pressures and wider macroeconomic troubles, the firm has still been able to keep dividends ticking higher. Indeed, the life insurer has raised the total dividend at a compound annual growth rate of 6.6% during the past five years, and City analysts expect payouts to keep on rolling.

City analysts forecast a full-year dividend of 16.9p per share in 2014, up 7% from last year’s levels, and an extra 7% advance is anticipated next year to 18p. As a consequence Standard Life’s chunky 4% yield for this year jumps to an even more appetising 4.2% for 2015.

The effect of pension changes in this year’s UK budget is likely to result in pressure at the firm’s domestic operations. But over the long-term I believe that Standard Life’s terrific product diversification should underpin strong earnings, and consequently dividend, expansion on a long-term time horizon.

Aviva

General insurance leviathan Aviva (LSE: AV) (NYSE: AV.US) has fallen out of favour with income investors in recent times, the business having slashed the payout in both 2013 and 2014 to boost the balance sheet and enhance its restructuring plan.

But City analysts expect the dividend to get rolling again from this year onwards as the business returns to a period of sustained earnings growth — the payout is expected to increase 15% this year, to 17.2p per share, and an additional 14% rise is anticipated for 2015 to 19.6p. These projections push a healthy yield of 3.4% for 2014 to a lip-smacking 3.9% for next year.

After Aviva nailed down terms for its £5.6bn takeover of Friends Life earlier this month, the business indicated that the move should give a further leg up to dividend growth. Should the takeover boost cost-cutting as planned and drive business volumes higher, I believe dividend hunters can looking forward to lucrative payout growth in the future.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »